← 홈

전체 프로그램

ADC 1068 · Antibody 5456 · CGT 2744 · 다음 갱신 D-12 · 마지막 7월 13일

인기최근 업데이트큐레이션임상 많은갱신 필요ORR최신Phase 3FDA승인프로그램 4,162개
CGTBiologicAbbVievedotin (RC48) with the est…Phase 2

Granulocyte Colony-Stimulating Factor (Granulocyte Colony-Stimulating Factor)

AML, Childhood; Aml · AML, Childhood

#AMLChildhood#CGT#Phase2#세포유전치료#CAR-T+5
효능 ORR 20.4%임상시험 32상태 RECRUITING
AntibodyBristol Myers SquibbPhase 2

nivolumab (Opdivo, Ipilimumab plus nivolumab)

Melanoma; Non Small Cell Lung Cancer · Melanoma

#Melanoma#Antibody#Phase2#항체#면역항체+3
효능 ORR 77.8%임상시험 32상태 RECRUITING
ADCBiologicJanssen Research & Development,…Phase 2

Nirogacestat (Nirogacestat)

Multiple Myeloma · Multiple Myeloma

#MultipleMyeloma#ADC#Phase2#항체약물접합체#antibody-drug-conjugate+2
효능 ORR 57%임상시험 32상태 RECRUITING
AntibodyBristol Myers SquibbPhase 2

nivolumab (Opdivo, Nivolumab plus Ipilimumab)

Lymphoma, Non-Hodgkin; Multiple Myeloma · Lymphoma, Non-Hodgkin

#LymphomaNon-Hodgkin#Antibody#Phase2#항체#면역항체+5
효능 ORR 77.8%임상시험 32상태 RECRUITING
AntibodyMerckVedotin or Chemotherapy in …Phase 2

pembrolizumab (Keytruda, Pembrolizumab - anti-PD-1 antibody)

Solid Tumor, Adult · PD-1

#PD-1#Antibody#Phase2#항체#면역항체+5
효능 ORR 11%임상시험 32상태 RECRUITING
ADCBiologicAkesoaxisPhase 3

Platinum chemotherapy (Platinum chemotherapy)

Advanced Non Small Cell Lung Cancer (NSCLC) · Advanced Non Small Cell Lung Cancer (NSC

#AdvancedNonSmallCellLungCancerNS#ADC#Phase3#항체약물접합체#antibody-drug-conjugate+3
효능 ORR 65.1%임상시험 32상태 RECRUITING
AntibodyRochevedotin-containing regimens…Phase 2

Rituximab and Bendamustine (Rituximab and Bendamustine)

Diffuse Large B-Cell Lymphoma; Follicular Lymphoma · MALT LYMPHOMA

#MALTLYMPHOMA#Antibody#Phase2#항체#면역항체+5
효능 ORR 90%임상시험 32상태 RECRUITING
AntibodyRochevedotin plus rituximab and …Phase 2

Rituximab and Lenalidomide (Rituximab and Lenalidomide)

Diffuse Large B-Cell Lymphoma; Follicular Lymphoma · Lymphoma of the Mucosa Associated Lympho

#LymphomaoftheMucosaAssociatedLym#Antibody#Phase2#항체#면역항체+5
효능 ORR 100%임상시험 32상태 RECRUITING
AntibodyRochederuxtecan, are effective i…Phase 2

trastuzumab (Herceptin, Trastuzumab plus Pertuzumab)

Lymphoma, Non-Hodgkin; Multiple Myeloma · Lymphoma, Non-Hodgkin

#LymphomaNon-Hodgkin#Antibody#Phase2#항체#면역항체+5
효능 ORR 79.5%임상시험 32상태 RECRUITING
AntibodyRocheVedotin-Based Polatuzumab V…Phase 2

rituximab, cyclophosphamide, doxorubicin, vincristine and prednisone (rituximab, cyclophosphamide, doxorubicin, vincristine and prednisone)

Diffuse Large B-Cell Lymphoma; Follicular Lymphoma · FRα

#FR#Antibody#Phase2#항체#면역항체+5
효능 ORR 76%임상시험 32상태 RECRUITING
AntibodyAnaveon AGVedotin ± Pe…Phase 2

KEYTRUDA® (ANV600 + pembrolizumab, ANV600 + pembrolizumab (KEYTRUDA®))

Advanced Solid Tumor · Advanced Solid Tumor

#AdvancedSolidTumor#Antibody#Phase2#항체#면역항체+4
효능 ORR 71.4%임상시험 31상태 RECRUITING
AntibodyETOP IBCSG Partners Foundationderuxtecan (Arm 4), followe…Phase 3

durvalumab (Imfinzi, Adjuvant durvalumab)

Non Small Cell Lung Cancer · Non Small Cell Lung Cancer

#NonSmallCellLungCancer#Antibody#Phase3#항체#면역항체+4
효능 ORR 45%임상시험 31상태 RECRUITING
AntibodyBiologicKyverna TherapeuticssPhase 2

Anti-CD20 mAB (Anti-CD20 mAB)

Multiple Sclerosis, Primary Progressive; Multiple Sclerosis, Secondary Progressive · CD20

#CD20#Antibody#Phase2#항체#면역항체+5
효능 ORR 89%임상시험 31상태 RECRUITING
ADCBiologicBeOne MedicinesPhase 1

Anticancer Agents (Anticancer Agents)

Advanced Solid Tumor · Advanced Solid Tumor

#AdvancedSolidTumor#ADC#Phase1#항체약물접합체#antibody-drug-conjugate+1
효능 0%임상시험 31상태 RECRUITING
AntibodyRochePhase 2

atezolizumab (Tecentriq, Atezolizumab - 21 Day Cycle)

Endometrial Cancer · Endometrial Cancer

#EndometrialCancer#Antibody#Phase2#항체#면역항체+3
효능 ORR 46.4%임상시험 31상태 RECRUITING
CGTBiologicVinmec Research Institute of St…Phase 1

Autologous CD19-Targeted CAR-T Cells (Autologous CD19-Targeted CAR-T Cells)

Refractory Systemic Lupus Erythematosus · CD19

#CD19#CGT#Phase1#세포유전치료#CAR-T+4
효능 ORR 92%임상시험 31상태 RECRUITING
CGTBiologicInstitute of Hematology & Blood…Phase 2

Autologous hematopoietic stem cell infusion (Autologous hematopoietic stem cell infusion)

Prolonged Cytopenia Following CAR-T Therapy · Prolonged Cytopenia Following CAR-T Ther

#ProlongedCytopeniaFollowingCAR-T#CGT#Phase2#세포유전치료#CAR-T+3
효능 ORR 73.33%임상시험 31상태 RECRUITING
CGTBiologicLiaoning Medical Diagnosis and …designPhase 2

Autologous immune Cells (Autologous immune Cells)

Lung Cancer (Locally Advanced or Metastatic); Liver Cancer (Locally Advanced or Metastatic) · Lung Cancer (Locally Advanced or Metasta

#LungCancerLocallyAdvancedorMetas#CGT#Phase2#세포유전치료#CAR-T+5
임상시험 31상태 RECRUITING
AntibodyEli LillyPhase 2

Cetuximab + mFOLFOX6 (Cetuximab + mFOLFOX6)

Neoadjuvant Treatment; Rectal Cancer · Metastatic Colorectal Cancer

#MetastaticColorectalCancer#Antibody#Phase2#항체#면역항체+4
효능 ORR 55%임상시험 31상태 RECRUITING
AntibodyRocheVedotin in Relapsed/Refract…Phase 2

Glofitamab/Obinutuzumab (Glofitamab/Obinutuzumab)

Richter Syndrome · FRα

#FR#Antibody#Phase2#항체#면역항체+5
효능 ORR 35.3%임상시험 31상태 RECRUITING

28 / 209 페이지

← 이전다음 →